Alnylam Pharmaceuticals Community
Create a narrative
WA
Based on Analyst Price Targets
Vutrisiran Poised To Transform Cardiomyopathy Treatment And Skyrocket Revenue Growth
US$285.91
FV
3.8% undervalued intrinsic discount16.91%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
1 day ago author updated this narrative